Is maternal thyrotropin releasing hormone administration safe in the pregnant woman with preeclampsia?
Maternal intravenous administration of thyrotropin releasing hormone (TRH) is associated with rapid elevations of blood pressure potentially causative of cerebrovascular accidents. We report a case in which peak blood pressure of 220/120 mm Hg was attained from a baseline of 132/80 mm Hg following TRH administration in a preeclamptic patient.
Tan
A S
AS
Department of Obstetrics and Gynecology, Yale-New Haven Hospital, Yale University School of Medicine, New Haven, Connecticut, USA.
Hsu
C D
CD
Marder
S
S
Copel
J A
JA
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D002561:Cerebrovascular Disorders / Q000139:chemically induced; D005260:Female; D005325:Fetal Organ Maturity / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000139:chemically induced*; D007231:Infant, Newborn; D007234:Infant, Premature; D007275:Injections, Intravenous; D008168:Lung / Q000187:drug effects / Q000196:embryology; D011175:Positive-Pressure Respiration; D011225:Pre-Eclampsia / Q000503:physiopathology*; D011247:Pregnancy; D012127:Respiratory Distress Syndrome, Newborn / Q000517:prevention & control; D012449:Safety; D013973:Thyrotropin-Releasing Hormone / Q000008:administration & dosage / Q000009:adverse effects*
D013973:Thyrotropin-Releasing Hormone